Lamotrigine
لاموتریژین
🧠 Nervous SystemAnticonvulsant / mood stabiliser
Market / country: 🇺🇸 USA
Lamictal (US)
🧮 Dose calculator
Bipolar disorder maintenance · Regimen source: FDA Lamotrigine · 2.4FDA Lamotrigine · 2.4, Table 5
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity (rash, angioedema, urticaria, mucosal ulceration) to lamotrigine. FDA Lamotrigine · 4
- ⚠️ Boxed warning: serious rash (SJS/TEN); 0.3–0.8% in children. Higher risk with valproate, high starting dose or rapid escalation. FDA Lamotrigine · Boxed Warning
Formulations
- 25 mg tablet — orally disintegrating tablet 🇺🇸 USA FDA Lamotrigine · 3
- 50 mg tablet — orally disintegrating tablet 🇺🇸 USA FDA Lamotrigine · 3
- 100 mg tablet — orally disintegrating tablet 🇺🇸 USA FDA Lamotrigine · 3
- 200 mg tablet — orally disintegrating tablet 🇺🇸 USA FDA Lamotrigine · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Lamotrigine · 8.1
“Risk Summary Data from several prospective pregnancy exposure registries and epidemiological studies of pregnant women have not detected an increased frequency of major congenital malformations or a consistent pattern of malformations among women exposed to lamotrigine compared with the general population (see Data ) .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Lamotrigine · 8.2
“Risk Summary Lamotrigine is present in milk from lactating women taking lamotrigine orally disintegrating tablets (see Data ) .”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Lamotrigine · Boxed Warning
“The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.3% to 0.8% in pediatric patients (aged 2 years to 17 years) and 0.08% to 0.3% in adults receiving lamotrigine.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Lamotrigine · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA219677
- DailyMed (FDA label)FDA Lamotrigine
- MedlinePlus (NIH)Lamotrigine
- WHO ATC/DDDN03AX09
- Darooyab (Iran)Lamotrigine
🇮🇷 Registered in Iran Darooyab · G-668/Lamotrigine
Dosage forms with Iranian generic codes, per Darooyab.
- 02150 · LAMOTRIGIN 10MG/ML ORAL SOLUTION · محلول خوراکی لاموتریجین ۱۰ میلیگرم / میلیلیتر
- 00732 · LAMOTRIGINE 100MG TAB · قرص لاموتریژین ۱۰۰ میلیگرم
- 17572 · LAMOTRIGINE 200MG TAB · قرص لاموتریژین ۲۰۰ میلیگرم
- 01991 · LAMOTRIGINE 25MG TAB · قرص لاموتریژین ۲۵ میلیگرم
- 00733 · LAMOTRIGINE 50MG TAB · قرص لاموتریژین ۵۰ میلیگرم
- 11824 · LAMOTRIGINE 600MG TAB · قرص لاموتریژین ۶۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Lamotrigine · 3FDA Lamotrigine · 2.4FDA Lamotrigine · 2.4, Table 5FDA Lamotrigine · 2.2, Tables 1–2FDA Lamotrigine · 4FDA Lamotrigine · Boxed WarningFDA Lamotrigine · 8.1FDA Lamotrigine · 8.2FDA Lamotrigine · 8.5FDA Lamotrigine · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-668/Lamotrigine
- Clinical review⚠ Unverified